MicroRNA-195作为中国癌症生存结局的预后因素：一项荟萃分析。

MicroRNA-195 as a prognostic factor for cancer survival outcome in China: a meta-analysis.

作者信息

Wang Ni, Cao Yang, Ge Xianxiu, Nie Junjie, Yu Yang, Li Quanpeng, Wang Fei, Miao Lin

机构信息

Medical Center for Digestive Diseases, Second Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, People's Republic of China.

Department of General Surgery, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, People's Republic of China.

出版信息

Cancer Manag Res. 2019 Aug 22;11:7967-7979. doi: 10.2147/CMAR.S205841. eCollection 2019.

DOI:10.2147/CMAR.S205841

PMID:31686911

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6709821/

Abstract

PURPOSE

MicroRNA-195 is dysregulated in different kinds of cancers and plays a pivotal role in tumorigenesis. It may function as a prognostic biomarker for cancers. However, the results from articles were not consistent. This study was designed to validate the prognostic value of microRNA-195 in human tumors.

METHODS

We conducted a detailed search on PubMed until December 31, 2018. The quality of these publications was assessed on the basis of a list of key reviews presented by PRISMA statement. The pooled hazard ratios (HR) and pooled odds ratios (OR) of each 95% confidence interval (95% CI) were calculated to assess the effect.

RESULTS

This meta-analysis included 12 studies involving 940 cancer patients to assess the prognostic value of miR-195 in different solid tumors. The results showed that patients with high expression of miR-195 had favorable tumor-node-metastasis (late vs early: pooled OR =0.16, 95% CI: 0.11-0.22, <0.001), lymph node metastasis (pooled OR =0.25, 95% CI: 0.18-0.35, <0.001) and distant metastasis (pooled OR =0.26, 95% CI: 0.13-0.52, <0.001). At the same time, high levels of miR-195 expression were closely correlated with better overall survival (pooled HR =0.46, 95% CI: 0.36-0.58, <0.001).

CONCLUSION

Elevated microRNA-195 may serve as a potential biomarker to predict a favorable prognosis for various cancer types in China.

摘要

目的

微小RNA-195在不同类型癌症中表达失调，在肿瘤发生过程中起关键作用。它可能作为癌症的预后生物标志物。然而，各文章的结果并不一致。本研究旨在验证微小RNA-195在人类肿瘤中的预后价值。

方法

我们在PubMed上进行了详细检索，直至2018年12月31日。根据PRISMA声明列出的关键评价清单对这些出版物的质量进行评估。计算每个95%置信区间（95%CI）的合并风险比（HR）和合并比值比（OR）以评估效应。

结果

这项荟萃分析纳入了12项研究，涉及940例癌症患者，以评估miR-195在不同实体瘤中的预后价值。结果显示，miR-195高表达的患者具有良好的肿瘤-淋巴结-转移情况（晚期与早期：合并OR =0.16，95%CI：0.11-0.22，<0.001）、淋巴结转移（合并OR =0.25，95%CI：0.18-0.35，<0.001）和远处转移（合并OR =0.26，95%CI：0.13-0.52，<0.001）。同时，miR-195高表达水平与更好的总生存期密切相关（合并HR =0.46，95%CI：0.36-0.58，<0.001）。